Mesoblast (MESO) Convertible Debt (2022 - 2025)
Mesoblast's (MESO) quarterly Convertible Debt came in at $5.7 million in Q4 2025, up 23.18% year-on-year from $4.6 million in Q4 2024, and up 23.18% quarter-over-quarter from $4.6 million in Q4 2024.
Mesoblast (MESO) Convertible Debt (2022 - 2025) Analysis & Trends
Mesoblast has disclosed Convertible Debt across 4 years of filings, most recently posting $5.7 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.72 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Dec 31, 2023 | 5.43 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | 2.19 Mn |